Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
162 hedge funds and large institutions have $1.23B invested in Aerie Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 49 increasing their positions, 35 reducing their positions, and 4 closing their positions.
1,450% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 4
300% more funds holding in top 10
Funds holding in top 10: 2 → 8 (+6)
151% more capital invested
Capital invested by funds: $489M → $1.23B (+$737M)
56% more funds holding
Funds holding: 104 → 162 (+58)
40% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 35
29% more call options, than puts
Call options by funds: $34.6M | Put options by funds: $26.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$17.6M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$15.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.3M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$11M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$9.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$26.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.91M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.27M |
| 4 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$4.54M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$4.4M |
AERI Hedge Fund Activity: Q3 2016 in Review
162 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2016, worth a combined $1.23B — up 151% from $489M a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new AERI positions and 4 closed out — a net gain of 58 holders — while 49 added to existing stakes and 35 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $17.6M. The largest seller was Deerfield Management, cutting an estimated $26.1M.
- 162 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2016, up from 104 in Q2 2016.
- Funds reported $1.23B of Aerie Pharmaceuticals stock for Q3 2016, up 151% quarter-over-quarter.
- 62 funds opened new Aerie Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +58 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2016 was OrbiMed, an estimated $17.6M added.
- The largest Aerie Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $26.1M sold.
Based on aggregated 13F filings for Q3 2016.